With Phase One for developing a blood test for early CWD detection essentially in their rearview mirror, scientists at Dream Genomics, a visionary biotech firm started in 2023 and based out of Northbrook, Illinois, are now deeply entrenched in Phase Two, Biological Confirmation. This second phase is moving ever closer to finishing up, explained Dr. Gary M. Pusateri, CEO and Founder of Dream Genomics. Biological confirmation, Phase Two, entails gathering sample after sample from virtually anywhere CWD is detected in the U.S. and Canada in whitetails, mule deer and elk, and pinning down the specific genes that distinguish themselves as being the answer to the diagnosis of CWD.
Phase Two has involved extensive travel, time, effort and research on behalf of Dr. Pusateri as well as Dr. Michael Falduto, Chief Technology Officer and Founder and Dr. Scott Magnuson, Chief Scientific Officer and Founder. The more testing that takes place during Phase Two, the closer they come to being 90 percent accurate (or better) as to which specific genes reveal the presence of CWD, regardless of the location a deer farmer raises deer. As this dedicated trio of scientists works diligently to finish Phase Two and continue onto Phase Three, Assay Development, they are very grateful for those investors who have allowed their work to move forward. However, they are also hopeful that new investors will contribute in order to more fully guarantee their work can be seen to full fruition. “We aren’t connected to a university,” Dr. Pusateri explained. “We currently rely on support from our investors, grants and self-funding for everything that we do.”
To come full circle in their game-changing quest, Phase Three, the final phase, involves moving accurate and targeted samples onto PCR plates. Assuming CWD positive genes become paired down to the fewest specific and acutely accurate number needed for testing, more tests could be run per plate, therefore not costing a deer farmer as much money to test their herd. “This is why Phase Two is so important,” Dr. Pusateri explained. “We want to ultimately be so accurate that both time and money are saved. We are doing whatever it takes to be at that point. We are looking at a 24-hour turnaround once Phase Three becomes fully operational.”
If any deer association, private individual or corporation is interested in donating or investing in Dream Genomics research, please contact Dr. Pusateri at his office at 847-291-9602 or his cell phone at 715-891-7878 or email him at gpusateri@dreamgx.com. Potential investors can also check out the website at www:dreamgx.com. “The best part about supporting our research is that you have two very large opportunities to gain,” Dr. Pusateri said. “One, in making live diagnostics available to all and helping the entire industry permanently move forward. Secondly, with potential personal gains from investing in the company. If the USDA accredits this test, a deer that tests negative could potentially be moved anywhere, opening doors for deer farmers to completely flourish rather than be held back by regulations.”
ILLINOIS